PDF(Pubmed)
Abstract：
Gemcitabine-induced hemolytic uremic syndrome is an often-missed condition. We present a case outlining the successful management of a patient with metastatic cholangiocarcinoma treated with gemcitabine who subsequently developed hemolytic uremic syndrome. Early recognition and stopping gemcitabine are essential in this patient population. Complement inhibitors have been used, and our patient improved on eculizumab therapy.
摘要：
吉西他滨诱导的溶血性尿毒综合征是一种经常错过的疾病。我们介绍了一个病例，概述了成功治疗接受吉西他滨治疗的转移性胆管癌患者，该患者随后发展为溶血性尿毒综合征。早期识别和停止吉西他滨对该患者人群至关重要。补体抑制剂已被使用，我们的患者在依库珠单抗治疗后有所改善。
